Investigational Immunotherapy Combo Shows Promise for Advanced Solid Tumors

(MedPage Today) -- An investigational combination of CTLA-4 and PD‐1 checkpoint inhibitors demonstrated "encouraging" tumor activity, as well as a manageable safety profile, in patients with advanced/metastatic solid tumors, according to...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news